Exosomes · Lesson 15 of 18 · 3 min

How strong is the clinical evidence for exosome therapy?

Where exosome research sits on the evidence pyramid, what the trial registry shows, and the main limitations of the studies published so far.

A gloved hand pipetting into small vials on a lab bench

Key takeaways.

  • The foundation of exosome research is preclinical: laboratory and animal studies.
  • Over 200 exosome trials were registered on ClinicalTrials.gov as of 2024, mostly early phase.
  • Most published human studies include fewer than fifty participants, and many fewer than twenty.
  • Case reports cannot establish efficacy because they have no control group.
  • Small studies give uncertain effect estimates and cannot reliably detect rare harms.
  • Exosomes remain investigational and are not FDA-approved for therapeutic use.

The evidence pyramid, applied to exosomes

Not all evidence carries equal weight. Animal studies show biological plausibility. Case reports and uncontrolled series give early signals but cannot separate a treatment effect from natural history, placebo response or regression to the mean.

Randomized controlled trials are the gold standard because randomization, control groups and blinding address those problems. Systematic reviews of good trials sit at the top.

Where exosomes sit today

Exosome therapy rests mainly on the lower levels. There are thousands of laboratory studies and hundreds of animal studies across cardiovascular, neurologic, wound, inflammatory and degenerative models.

Human research is growing. More than 200 trials were registered on ClinicalTrials.gov as of 2024. Most therapeutic trials are Phase I or II, designed to establish safety and look for preliminary signals. Published clinical studies include early work in severe COVID-19 lung injury and graft-versus-host disease.

Limitations to look for

Small sample size is the most pervasive limitation. Small studies lack statistical power, produce wide confidence intervals, and cannot reliably detect rare but important adverse events.

Other challenges are specific to a new biologic. Manufacturing standardization, potency assessment and optimal dosing are not fully worked out, which makes studies hard to compare.

What this means for practice

Critical appraisal is the core skill here. Commercial interest and social media can amplify preliminary findings beyond what they support.

The evidence does not yet support moving exosomes from investigational therapy to established treatment. Exosome therapies are not FDA-approved for therapeutic use.

Educational content for healthcare professionals. Not a treatment recommendation. Exosome therapies are not FDA-approved for therapeutic use.

Exosomes: 0 of 18 lessons finished

All lessons

This guide covers the what and the why.

The how is taught live. The webinar and live training go deeper on:

  • Walking through the key published studies and their limits
  • Ongoing trials to watch
  • A framework for appraising new exosome papers
  • Applying evidence grading to clinical decisions

Common questions.

Are there randomized controlled trials of exosome therapy?
Most registered therapeutic trials are early phase, and most published human studies are small. The larger definitive trials needed for approval largely remain to be done.
How many exosome clinical trials are there?
Over 200 trials involving exosomes were registered on ClinicalTrials.gov as of 2024. That count includes both therapeutic and diagnostic biomarker studies.
Can I rely on case reports of exosome treatment?
Case reports are useful for generating hypotheses and flagging safety signals. They cannot establish efficacy or support clinical recommendations, because they lack control groups.

Sources

  • Sengupta, V., et al. (2020). Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19. Stem Cells and Development, 29(12), 747-754.
  • Kordelas, L., et al. (2014). MSC-derived exosomes: a novel tool to treat therapy-refractory graft-versus-host disease. Leukemia, 28(4), 970-973.
  • Wiklander, O. P. B., et al. (2019). Advances in therapeutic applications of extracellular vesicles. Science Translational Medicine, 11(492), eaav8521.

Ready for the hands-on detail?

Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.